3-Benzyl-6-Bromo-2-Chloroquinoline CAS 654655-68-2 Pite ≥99.0% (HPLC) Faktori
Entèmedyè ki gen rapò ak pwovizyon komèsyal yo:
3-Benzyl-6-Bbromo-2-Mmethoxyquinoline CAS: 654655-69-3
3-Benzyl-6-Bromo-2-Chloroquinoline CAS: 654655-68-2
TMC207 CAS 843663-66-1
CAS: 845533-86-0
| Non Chimik | 3-Benzyl-6-Bromo-2-Chloroquinoline |
| Sinonim | 6-Bromo-2-Chloro-3-(Phenylmethyl)quinoline |
| Nimewo CAS | 654655-68-2 |
| Nimewo CAT | RF-PI107 |
| Estati Stock | Nan Stock, Pwodiksyon Echèl Jiska Tòn |
| Fòmil molekilè | C₁₆H₁₁BrClN |
| Pwa molekilè | 332.62 |
| Mak | Ruifu Chimik |
| Atik | Espesifikasyon |
| Aparans | Poud blan pou blan oswa limyè jòn |
| Pite / Metòd analiz | ≥99.0% (HPLC) |
| Pwen k ap fonn | 100.0 ~ 120.0 ℃ |
| Imidite (KF) | ≤0.50% |
| Rezid sou ignisyon | ≤0.50% |
| Enpurte total | ≤1.00% |
| Tès Creole | Enterprise Standard |
| Itilizasyon | Entèmedyè API (CAS: 845533-86-0) |
3-Benzyl-6-bromo-2-Chloroquinoline (CAS: 654655-68-2) se yon entèmedyè prensipal nan API (CAS: 845533-86-0).API (CAS: 845533-86-0) se yon dwòg diarylquinone devlope pa Janssen Pharmaceutical.Medikaman an, ki te apwouve an 2012 pou tretman tibèkiloz ki reziste plizyè dwòg (MDR-TB), te devlope an patenarya ak Johnson & Johnson e li reprezante premye nouvo terapi tibèkiloz ki te apwouve nan plis pase kat deseni.API (CAS: 845533-86-0) yo itilize nan terapi konbinezon pou tretman tibèkiloz poumon ki reziste milti-dwòg pa anpèchman ATP synthase, yon anzim esansyèl pou replikasyon mikobakteri.
